Life Molecular Imaging started recruitment for longitudinal Phase 2 study with the Tau tracer PI-2620

Tuesday, September 17, 2019 Research News
Email Print This Page Comment bookmark
Font : A-A+

The new study will thoroughly assess the accumulation and spread of Tau depositions in patients with Alzheimer's disease and in subjects with mild cognitive impairment as visualized by PI-2620 brain uptake

BERLIN, Germany and LONDON, United Kingdom, Sept. 17, 2019 /PRNewswire-PRWeb/ -- Life Molecular Imaging (LMI) today announced the commencement of recruitment for a Phase 2 study to further investigate PI-2620 in Alzheimer's disease.

Tau depositions, in conjunction with beta-amyloid plaques, represent the critical pathologies in Alzheimer's disease (AD). The potential of PI-2620 to visualize Tau deposition in AD and non-AD tauopathies has already been demonstrated with detecting both 3R and 4R related Tau depositions. The Phase 2 study aims to further investigate the spread of the Tau signal in mild cognitive impairment (MCI) and mild to moderate AD subjects and to monitor the change of signal over time.

"This clinical trial will help to gain a better understanding of the performance of PI-2620 in AD. As a next generation Tau PET tracer, PI-2620 has the potential to provide a better understanding of the accumulation of Tau in the brain and change over time. PI-2620 could enable an earlier and more accurate diagnosis of AD and other neurodegenerative disorders and could be used to monitor the effect of novel treatments on Tau accumulation", said Andrew Stephens, MD, Ph.D., Chief Medical Officer at LMI.

The Phase 2 study will be performed in the UK taking advantage of LMI's and Alliance Medical Group's combined expertise, radiopharmacies and imaging centers.

Ludger Dinkelborg, Ph.D., Managing Director at LMI added, "The start of this longitudinal Phase 2 study is an important milestone for Life Molecular Imaging and demonstrates our commitment to research and development of innovative imaging solutions. We are particularly excited about being able to leverage the LMI/Alliance partnership to provide new tracers, manufacturing and imaging under one umbrella organization".

Life Molecular Imaging, together with its academic and industrial manufacturing partners, has established a global supply network making PI-2620 available in the US, Canada, Europe, China, Thailand, South Korea, Japan and Australia for research and clinical trials of pharma companies.

About PI-2620 Tau deposits, in conjunction with beta-amyloid plaques, represent the other pathological hallmark of Alzheimer's disease, with Tau deposits further playing an important role in other neurodegenerative diseases. PI-2620 is binding to Tau deposits and is a next generation 18F-labeled investigational PET tracer with favourable properties and imaging characteristics. It was discovered and developed in a research collaboration between Life Molecular Imaging and AC Immune SA, a Swiss-based clinical stage biopharmaceutical company. Life Molecular Imaging has the exclusive, world-wide license for research, development and commercialization of Tau PET tracers generated within the discovery program.

About Life Molecular Imaging (LMI) Life Molecular Imaging (LMI, formerly Piramal Imaging) was formed in 2012 with the acquisition of the molecular imaging research and development portfolio of Bayer Pharma AG. It is now part of the Alliance Medical Group (a member of the Life Healthcare Group) offering an integrated business including research and development laboratories, a network of cyclotrons, radiopharmacies and imaging facilities. By developing novel PET tracers for Molecular Imaging, LMI is focusing on a key field of modern medicine. The organization strives to be a leader in the Molecular Imaging field by developing innovative products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. Please visit

About Alliance Medical Alliance Medical, a Division of Life Healthcare Group, is Europe's leading diagnostic and molecular imaging services provider delivering high quality diagnostic solutions in partnership with public and private organisations. It provides PET/CT services at over 60 locations and operates 10 radiopharmacies producing a range of Radiopharmaceuticals for PET/CT imaging across Europe, including the National PET/CT Contract in England which provides PET/CT scans for 60% of the English population. Please visit

About Life Healthcare Group The Life Healthcare Group has more than 33 years' experience in the private healthcare and hospital industry. Headquartered in Johannesburg, South Africa, the Group is a listed company on the Johannesburg Stock Exchange. The company's primary business is private acute hospital care with 65 healthcare facilities in seven of South Africa's nine provinces and one hospital in Botswana, as well as providing services for acute physical rehabilitation, acute mental healthcare and renal dialysis. Life Employee Health Solutions services both occupational health and employee wellness to private and public employers. The Group includes an international presence through Alliance Medical Group (UK/Europe) and Scanmed S.A. (Poland). For more information visit

For media queries Nicole Fletcher | Marketing Communications | Life Molecular Imaging Tel#: 857-202-1122 |


SOURCE Life Molecular Imaging

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z



Premium Membership Benefits

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store